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When new scientific discoveries are properly evaluated
within the translational research continuum and definitive
evidence is generated regarding the balance of benefits
and risks associated with therapeutic interventions, dra-
matic health improvements are seen both for individuals
and populations. Until recently, however, technological
limitations dictated that definitive evidence could be gen-
erated for only a fraction of interventions under develop-
ment, because clinical investigation was limited by
geography and access to expertise. Today, less than 15% of
major medical decisions are informed by high-quality evi-
dence [1]. Furthermore, increasing knowledge about the
roles played by genetics and practice environments
demonstrates that we must develop multinational studies
to generate evidence relevant to particular biological and
cultural contexts [2]. It is now time to begin to plan for a
global learning health system.
Modern informatics and information technology have
enabled the sharing of research data without regard to
geographic boundaries. These new capabilities expand the
concept of human biomedical research from an activity
conducted in a limited number of specialized centers to a
global activity accessible to all patient populations and
qualified practitioners [3]. With appropriate informatics
support, shared protocols, and facilitative cultural ele-
ments, common diseases can be studied on a larger scale
and clinical trials in rare diseases will be able to accrue
adequate sample sizes, enabling valid inferences to be
drawn. In essence, the limits on knowledge generation will
henceforth be determined by two key factors: (1) the num-
ber of qualified individuals in the clinical and translational
research workforce and (2) the degree to which regulatory
and funding sources encourage broad-scale collaboration.
Examples of therapeutic areas where progress could be
accelerated include diabetes (which affects global popu-
lations in large numbers), congenital heart disease
(which affects 1% of all global populations) and Pompe
disease (a rare disease with a new effective therapy). In
each case, collaborative studies between China and the
United States—two of the world’s largest funders of bio-
medical research—could provide the example to stimu-
late similar activity on a global scale.
We propose that five key programs specific to clinical
and translational research [4] (Table 1) will need to
train and educate a vast workforce over the coming dec-
ade in order to capitalize on these technological
advances.
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